Which medication ends with -gliflozin and reduces renal glucose reabsorption?

Which medication ends with -gliflozin and reduces renal glucose reabsorption?

• A. Metformin
• B. Sitagliptin
• C. Canagliflozin
• D. Acarbose

Answer: (C)

Drugs with the suffix -gliflozin are SGLT2 inhibitors that block the reabsorption of glucose in the kidney’s proximal tubule. By inhibiting this transporter, more glucose is excreted in the urine, which lowers blood glucose levels in type 2 diabetes. Canagliflozin specifically is an -gliflozin drug and acts as an SGLT2 inhibitor, reducing renal glucose reabsorption. Metformin lowers blood glucose mainly by reducing hepatic glucose production and improving insulin sensitivity, not by changing kidney glucose reabsorption. Sitagliptin is a DPP-4 inhibitor that increases incretin levels to boost insulin secretion and suppress glucagon, with no effect on renal glucose reabsorption. Acarbose slows carbohydrate absorption in the gut by inhibiting alpha-glucosidase, not the kidney’s glucose reabsorption.

Drugs with the suffix -gliflozin are SGLT2 inhibitors that block the reabsorption of glucose in the kidney’s proximal tubule. By inhibiting this transporter, more glucose is excreted in the urine, which lowers blood glucose levels in type 2 diabetes.

Canagliflozin specifically is an -gliflozin drug and acts as an SGLT2 inhibitor, reducing renal glucose reabsorption. Metformin lowers blood glucose mainly by reducing hepatic glucose production and improving insulin sensitivity, not by changing kidney glucose reabsorption. Sitagliptin is a DPP-4 inhibitor that increases incretin levels to boost insulin secretion and suppress glucagon, with no effect on renal glucose reabsorption. Acarbose slows carbohydrate absorption in the gut by inhibiting alpha-glucosidase, not the kidney’s glucose reabsorption.